Results 21 to 30 of about 674,512 (170)

Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine

Genome Medicine, 2023
Background Prostate cancer (PrCa) genomic heterogeneity causes resistance to therapies such as androgen deprivation. Such heterogeneity can be deciphered in the context of evolutionary principles, but current clinical trials do not include evolution as ...
Anssi Nurminen, Serafiina Jaatinen, Sinja Taavitsainen, Gunilla Högnäs, Tom Lesluyes, Naser Ansari-Pour, Teemu Tolonen, Kerstin Haase, Antti Koskenalho, Matti Kankainen, Juho Jasu, Hanna Rauhala, Jenni Kesäniemi, Tiia Nikupaavola, Paula Kujala, Irina Rinta-Kiikka, Jarno Riikonen, Antti Kaipia, Teemu Murtola, Teuvo L. Tammela, Tapio Visakorpi, Matti Nykter, David C. Wedge, Peter Van Loo, G. Steven Bova   +24 more
doaj   +1 more source

Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review

BJUI Compass
Objective To analyse the latest evidence on the relative harms and benefits of screening and diagnostic pathways with close examination of (i) men aged 50 years or older, (ii) men whose ethnicity places them at higher risk and (iii) men with a family ...
Abel Tesfai, Natalia Norori, Thomas A. Harding, Yui Hang Wong, Matthew David Hobbs   +4 more
doaj   +1 more source

Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

Nature Communications, 2018
Prostate cancer often develops resistance to androgen receptor (AR) targeting drugs. Here, the authors show that, under conditions of hypoxia, AR inhibition via enzalutamide increases the expression of the glycolytic enzyme phosphoglucose isomerase (GPI)
Hao Geng, Changhui Xue, Janet Mendonca, Xiao-Xin Sun, Qiong Liu, Patrick N. Reardon, Yingxiao Chen, Kendrick Qian, Vivian Hua, Alice Chen, Freddy Pan, Julia Yuan, Sang Dang, Tomasz M. Beer, Mu-Shui Dai, Sushant K. Kachhap, David Z. Qian   +16 more
doaj   +1 more source

Supporting Patients With Untreated Prostate Cancer on Active Surveillance: What Causes an Increase in Anxiety During the First 10 Months?

Frontiers in Psychology, 2020
BackgroundThe psychological burden possibly deriving from not immediately undergoing radical treatment for prostate cancer (PCa) could be a potential disadvantage of active surveillance (AS), especially in the eve of some relevant clinical exams [i.e ...
Maria Francesca Alvisi, Paola Dordoni, Tiziana Rancati, Barbara Avuzzi, Nicola Nicolai, Fabio Badenchini, Letizia De Luca, Tiziana Magnani, Cristina Marenghi, Julia Menichetti, Villa Silvia, Zollo Fabiana, Salvioni Roberto, Valdagni Riccardo, Valdagni Riccardo, Valdagni Riccardo, Bellardita Lara, the Prostate Cancer Multidisciplinary Clinic Working Group   +17 more
doaj   +1 more source

The impact of pre‐biopsy MRI and additional testing on prostate cancer screening outcomes: A rapid review

BJUI Compass
Objective This work aims to examine the latest evidence on the impact of pre‐biopsy MRI, in addition to prostate‐specific antigen (PSA) testing, on health outcomes and quality of life.
Abel Tesfai, Natalia Norori, Thomas A. Harding, Yui Hang Wong, Matthew David Hobbs   +4 more
doaj   +1 more source

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology

Nature Communications, 2021
The prognosis of castration-resistant prostate cancers remains dismal, but accurate preclinical models can lead to effective therapies. Here the Melbourne Urological Research Alliance establish prostate cancer patient-derived xenografts, use the tumors ...
Gail P. Risbridger, Ashlee K. Clark, Laura H. Porter, Roxanne Toivanen, Andrew Bakshi, Natalie L. Lister, David Pook, Carmel J. Pezaro, Shahneen Sandhu, Shivakumar Keerthikumar, Rosalia Quezada Urban, Melissa Papargiris, Jenna Kraska, Heather B. Madsen, Hong Wang, Michelle G. Richards, Birunthi Niranjan, Samantha O’Dea, Linda Teng, William Wheelahan, Zhuoer Li, Nicholas Choo, John F. Ouyang, Heather Thorne, Lisa Devereux, Rodney J. Hicks, Shomik Sengupta, Laurence Harewood, Mahesh Iddawala, Arun A. Azad, Jeremy Goad, Jeremy Grummet, John Kourambas, Edmond M. Kwan, Daniel Moon, Declan G. Murphy, John Pedersen, David Clouston, Sam Norden, Andrew Ryan, Luc Furic, David L. Goode, Mark Frydenberg, Mitchell G. Lawrence, Renea A. Taylor   +44 more
doaj   +1 more source

Using real world data to bridge the evidence gap left by prostate cancer screening trials

ESMO Real World Data and Digital Oncology
Background and purpose: Population-based prostate cancer screening is currently not recommended in the UK because harms may outweigh benefits. Recent changes to the diagnostic pathway have improved safety and accuracy, but uncertainty remains as to how ...
N. Norori, N. Burns-Cox, L. Blaney, N. Mayor, A. Rylance, T.T. Shah, A. Naranjo, M.D. Hobbs   +7 more
doaj   +1 more source

A Surgically Treated Case of Ureterovesical Amyloidosis of the Bladder in a Patient with Idiopathic Thrombocytopenia

Case Reports in Urology, 2018
Idiopathic thrombocytopenia (ITP) is a bleeding disorder involving the destruction of platelets by the immune system. Systemic amyloidosis is another bleeding disorder involving amyloid deposits that create defects in coagulation and increased ...
Sung Han Kim, Weon Seo Park, Jae Young Joung, Kang Hyun Lee, Jinsoo Chung, Ho Kyung Seo   +5 more
doaj   +1 more source

The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer

Diagnostics, 2020
Radical prostatectomy (RP) is a curatively intended treatment option for clinically localized non-metastatic prostate cancer (PCa). Novel biomarkers could refine treatment choice based on a better identification of men at risk of biochemical recurrence ...
Hein Vincent Stroomberg, Gitte Kristensen, Kasper Drimer Berg, Solvej Lippert, Klaus Brasso, Martin Andreas Røder   +5 more
doaj   +1 more source

Irradiation of prostate cancer alters circulating small extracellular vesicle functions

Scientific Reports
It is known that β1 integrins and a downstream signaling molecule c-Src are upregulated in prostate cancer (PrCa) tissues, are co-expressed in circulating small extracellular vesicles (sEVs) and contribute to cancer progression. Here, we demonstrate that
Aejaz Sayeed, Vaughn Garcia, Cecilia E. Verrillo, Rachel M. DeRita, Md Niamat Hossain, Shiv Ram Krishn, Samuel Sey, Christopher D. Shields, Adrian D. Altieri, Qin Liu, Khalid Sossey-Alaoui, William K. Kelly, Lucia R. Languino   +12 more
doaj   +1 more source